Long Ideas - Keryx BioPharmaceuticals (NASDAQ:KERX) miscalculated the timing for when its CRO (contract research organization) would deliver Phase III results for Zerenex, the company’s phosphate-binder candidate for … Continue Reading
Read NowLong Ideas - XenoPort (NASDAQ:XNPT) will deliver Phase III trial results for its lead pipeline candidate, Arbaclofen Placarbil, in early 2Q, and the company is moving forward on … Continue Reading
Read NowLong Ideas - Shares of Navidea Biopharmaceuticals (NASDAQ:NAVB) are ready to climb as the PDUFA (FDA action) date for the company’s lead product, Lymphoseek, is approaching. This is … Continue Reading
Read NowLong Ideas - InterMune (NASDAQ:ITMN) just announced very favorable pricing on their latest round of financing. The company sold $105 million aggregate principal amount of its 2.5% senior … Continue Reading
Read NowLong Ideas - In medicine, there are certain watershed moments that become an enduring part of medical history, such as the discovery of penicillin, or the eradication of … Continue Reading
Read NowLong Ideas - ViroPharma (NASDAQ:VPHM) updated investors last week at the JP Morgan Healthcare conference, offering 2013 guidance for lead product Cinryze, which was strong. The company expects … Continue Reading
Read NowLong Ideas - Halozyme Therapeutics (NASDAQ:HALO) will likely continue to move higher Monday after an upgrade from BMO Capital Markets, which has increased its outlook from Neutral to … Continue Reading
Read Now